Literature DB >> 24668329

Clinical trial results: a clinical trial bazaar!

Antonio Tito Fojo1, Susan E Bates.   

Abstract

Mesh：

Year:  2014        PMID： 24668329      PMCID： PMC3983835          DOI： 10.1634/theoncologist.2014-0091

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  7 in total

1.  Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.

Authors:  Makoto Maemondo; Akira Inoue; Shunichi Sugawara; Toshiyuki Harada; Yuji Minegishi; Kazuhiro Usui; Koji Miwa; Naoto Morikawa; Mariko Kambe; Kenji Ube; Kana Watanabe; Osamu Ishimoto; Tomohiro Sakakibara; Akihiko Gemma; Toshihiro Nukiwa
Journal:  Oncologist       Date:  2014-03-28

2.  Mitomycin C and high-dose 5-fluorouracil with folinic acid as a therapeutic option for heavily pretreated patients with metastatic colorectal cancer: prospective phase II trial.

Authors:  Rafał Stec; Lubomir Bodnar; Marta Smoter; Jan Korniluk; Agata Kuchar; Beata Młot; Cezary Szczylik
Journal:  Oncologist       Date:  2014-03-28

3.  Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Authors:  Beverly Moy; Patrick Neven; Fabienne Lebrun; Meritxell Bellet; Binghe Xu; Tomasz Sarosiek; Louis Chow; Paul Goss; Charles Zacharchuk; Eric Leip; Kathleen Turnbull; Nathalie Bardy-Bouxin; Ladan Duvillié; István Láng
Journal:  Oncologist       Date:  2014-03-27

4.  An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.

Authors:  Rocio Garcia-Carbonero; Fernando Rivera; Joan Maurel; Jean-Pierre M Ayoub; Malcolm J Moore; Andres Cervantes; Timothy R Asmis; Jonathan D Schwartz; Federico Nasroulah; Shaila Ballal; Josep Tabernero
Journal:  Oncologist       Date:  2014-03-27

5.  Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.

Authors:  Francesca Toffalorio; Gianluca Spitaleri; Chiara Catania; Laura Dal Zotto; Cristina Noberasco; Angelo Delmonte; Mariacarmela Santarpia; Fabio Vecchio; Veronica Brunelli; Cristiano Rampinelli; Massimo Barberis; Caterina Fumagalli; Massimo Zucchetti; Monique Zangarini; Tullia Diena; Romano Danesi; Filippo de Braud; Tommaso De Pas
Journal:  Oncologist       Date:  2014-03-27

6.  A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.

Authors:  Elizabeth R Plimack; Tingting Tan; Yu-Ning Wong; Margaret M von Mehren; Lois Malizzia; Susan K Roethke; Samuel Litwin; Tianyu Li; Gary R Hudes; Naomi B Haas
Journal:  Oncologist       Date:  2014-03-27

7.  Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Authors:  Beverly Moy; Patrick Neven; Fabienne Lebrun; Meritxell Bellet; Binghe Xu; Tomasz Sarosiek; Louis Chow; Paul Goss; Charles Zacharchuk; Eric Leip; Kathleen Turnbull; Nathalie Bardy-Bouxin; Ladan Duvillié; István Láng
Journal:  Oncologist       Date:  2014-03-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.